A simple blood test capable of identifying a glioma over other neoplasms and also being able to identify the IDH status may provide a non-intrusive way by which patients can be stratified early on in the treatment process without having to undergo invasive biopsies or time-consuming scans. This evidence concerns the gene IDH2 and central nervous system cancer.